The state of Oregon currently has 16 active clinical trials seeking participants for Pancreatic Cancer research studies. These trials are conducted in various cities, including Portland, Eugene, Medford and Clackamas.
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT05259696
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Providence Cancer Institute, Portland, Oregon
Conditions: Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
Register for Updates
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT05034627
Recruiting
This phase I trial tests the safety, side effects, and best dose of calaspargase pegol-mknl in combination with cobimetinib in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Cobimetinib attacks a protein called MEK that has been known to stimulate cells that promote the growth of cancer cells in the body. Calaspargase pegol-mknl is an enzyme that converts the amino acid L-asparagi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/12/2023
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Register for Updates
Study of Effect of Azeliragon in Patients Refractory to First-Line Metastatic Pancreatic Cancer
NCT05766748
Recruiting
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line or second-line treatment of metastatic pancreatic cancer.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
10/09/2023
Locations: Williamette Valley Cancer Institute and Research Center, Eugene, Oregon
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03257033
Recruiting
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2022
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Locally Advanced Pancreatic Cancer
Register for Updates